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BACKGROUND: We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin
(XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer.
METHODS: NO16966 was a randomised, two-arm, non-inferiority, phase III comparison of XELOX vs FOLFOX4, which was
subsequently amended to a 2 2 factorial design with further randomisation to bevacizumab or placebo. A planned follow-up
exploratory analysis of OS was performed.
RESULTS: The intent-to-treat (ITT) population comprised 2034 patients (two-arm portion, n¼634; 2 2 factorial portion, n¼1400).
For the whole NO16966 study population, median OS was 19.8 months in the pooled XELOX/XELOX-placebo/XELOX-
bevacizumab arms vs 19.5 months in the pooled FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab arms (hazard ratio 0.95
(97.5% CI 0.85–1.06)). In the pooled XELOX/XELOX-placebo arms, median OS was 19.0 vs 18.9 months in the pooled FOLFOX4/
FOLFOX4-placebo arms (hazard ratio 0.95 (97.5% CI 0.83–1.09)). FOLFOX4 was associated with more grade 3/4 neutropenia/
granulocytopenia and febrile neutropenia than XELOX, and XELOX with more grade 3 diarrhoea and grade 3 hand-foot syndrome
than FOLFOX4.
CONCLUSION: Updated survival data from study NO16966 show that XELOX is similar to FOLFOX4, confirming the primary analysis
of progression-free survival. XELOX can be considered as a routine first-line treatment option for patients with metastatic colorectal
cancer.
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Capecitabine (Xeloda; F. Hoffmann–La Roche, Basel, Switzerland)
is an oral fluoropyrimidine with similar efficacy to bolus
5-fluorouracil/folinic acid (5-FU/FA) in the first-line treatment of
metastatic colorectal cancer (Hoff et al, 2001; van Cutsem et al,
2001) and as adjuvant therapy for stage III colon cancer (Twelves
et al, 2005). The efficacy of capecitabine and a 3-weekly dose
of oxaliplatin (XELOX regimen) is also non-inferior to 5-FU/FA
plus oxaliplatin (FOLFOX4 or FOLFOX6) in the first- and second-
line treatment of patients with metastatic colorectal cancer
(Rothenberg et al, 2008; Cassidy et al, 2008a; Ducreux et al, 2011).
The largest of the recent trials evaluating XELOX, NO16966
(XELOX-1), started as a two-arm, randomised, non-inferiority,
phase III study designed to compare XELOX with FOLFOX4 as
first-line treatment for metastatic colorectal cancer. The protocol
was subsequently amended to include the further addition of
bevacizumab or placebo using a 2 2 factorial design. The study
had two co-primary objectives: (1) to evaluate the non-inferiority
of XELOX ± bevacizumab vs FOLFOX4 ± bevacizumab; and
(2) to evaluate the superiority of bevacizumab vs placebo when
combined with oxaliplatin-based chemotherapy (i.e., XELOX or
FOLFOX4). The results pertaining to both objectives have been
previously published (Saltz et al, 2008; Cassidy et al, 2008a). The
present paper describes an updated analysis of overall survival
(OS) for the comparison of XELOX/XELOX-placebo/XELOX-
bevacizumab vs FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizu-
mab from study NO16966.
PATIENTS AND METHODS
The methods of this trial have been described in detail previously
(Saltz et al, 2008; Cassidy et al, 2008a). The study was performed in
accordance with the Declaration of Helsinki and Good Clinical
Practice Guidelines. Written informed consent was obtained from
all patients participating in the study. Approval of the protocol was
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sobtained from an independent ethics committee or institutional
review board of each site.
Patient population
Patients X18 years of age with histologically confirmed, unresec-
table metastatic colorectal cancer (X1 unidimensionally measur-
able lesion), an ECOG performance status of p1 and a life
expectancy of 43 months were eligible. No previous systemic
therapy for metastatic disease or previous oxaliplatin or bevaci-
zumab were allowed. Patients were required to have adequate
haematologic/clotting, hepatic and renal function. Patients were
excluded if they had any of the following: clinically significant
cardiovascular disease; clinically detectable ascites; use of full-dose
anticoagulants or thrombolytics; known CNS metastases; serious
non-healing wound, ulcer or bone fracture; known bleeding
diathesis or coagulopathy; and proteinuria X500mg per 24h.
Treatment plan
Patients were randomly assigned to treatment using an interactive
voice response system. Randomisation was stratified by region,
ECOG performance status, liver as a metastatic site, number of
metastatic sites (organs) and alkaline phosphatase level.
XELOX consisted of a 2-h intravenous infusion of oxaliplatin
130mgm
–2 on day 1 plus oral capecitabine 1000mgm
–2 twice
daily for 2 weeks as a 3-week cycle. The first dose of capecitabine
was given in the evening of day 1 and the last dose on the morning
of day 15. The FOLFOX4 regimen has been previously described
(de Gramont et al, 2000). After amendment of the study protocol,
bevacizumab (7.5mgkg
–1every third week) or placebo was added
to XELOX, and bevacizumab (5mgkg
–1 every second week) or
placebo to FOLFOX4. Bevacizumab or placebo was given as a 30-
to 90-min intravenous infusion on day 1 of each cycle before
oxaliplatin.
Treatment was continued until disease progression or for 48
weeks, whichever came first (study treatment phase). Patients who
completed the 48-week treatment phase without disease progres-
sion were eligible to continue treatment until progression (post-
study treatment phase). Patients whose tumour became operable,
and for whom resection was performed, were allowed to enter the
post-study treatment phase.
Assessments
Tumour assessments (CT scan, MRI) were performed within 28
days before starting study treatment and repeated after every two
XELOX cycles and every three FOLFOX4 cycles (i.e., every sixth
week in both arms), and at the end of treatment. After completion
of study treatment, patients were followed every 3 months until
disease progression and/or death.
Patients were evaluated for adverse events during therapy and
until 28 days after the last study drug dose. Adverse events were
graded according to National Cancer Institute Common Toxicity
Criteria (NCI-CTC), version 3. Predefined adverse events of special
interest for chemotherapy were: grade 3/4 neutropenia/granulo-
cytopenia; grade 3/4 neurosensory toxicity; grade 3/4 diarrhoea;
grade 3/4 vomiting/nausea; grade 3/4 stomatitis and grade 3 hand-
foot syndrome.
Statistical analysis
The intent-to-treat (ITT) patient population included all patients
who underwent randomisation and signed the informed consent
form. The eligible patient population (EPP) was the ITT
population minus patients who did not receive at least one dose
of study drug, and those patients who violated major protocol
inclusion/exclusion criteria. As the results for the EPP population
were the same as for the ITT population, ITT data only will be
presented in this paper. The safety population included all patients
receiving at least one dose of study drug.
Overall survival was defined as the time from the date of
randomisation to the date of death. Patients who were not reported
as having died at the time of the analysis were censored using the
date they were last known to be alive. Overall survival was analysed
using a Cox model and presented as Kaplan–Meier estimates with
hazard ratios (HRs) and 97.5% confidence intervals (CIs).
The primary analysis of NO16966 was event driven and was
performed on 31 January 2006 when 1200 progression-free survival
events had occurred in the EPP; this approach ensured 90% power
at an a level of 2.5 (Saltz et al, 2008). A further planned follow-up
analysis of OS was performed at the time of the 4-month safety
update.
As the study was not powered for formal testing of non-
inferiority for OS, the OS analysis is exploratory and the results
described by Kaplan–Meier estimates with HRs and 97.5% CIs.
An additional exploratory analysis of OS was performed to control
for any possible crossover effects of FOLFOX in patients who
received XELOX as their first-line regimen. In this analysis,
patients in the XELOX arms who received FOLFOX4 or similar
regimen as second-line therapy were censored.
RESULTS
Patient population
Between July 2003 and May 2004, 634 patients were randomised in
the two-arm portion of the study. Between February 2004 and
February 2005, a further 1400 patients were randomised in the
2 2 factorial part of the study. Overall, 2034 patients made up the
ITT population (Figure 1). The baseline demographic and clinical
characteristics were well balanced between treatment arms
(Table 1).
Treatment exposure and second-line therapy
The median dose intensities (ratio of dose received to dose
planned) of 5-FU, capecitabine, oxaliplatin and bevacizumab were
X0.89 in all treatment arms. The median number of cycles
administered was 11 (range 1–24) in the FOLFOX4/FOLFOX4-
placebo group, 12 (range 1–25) in the FOLFOX4-bevacizumab
group, 7 (range 1–18) in the XELOX/XELOX-placebo group and
8 (range 1–17) in the XELOX-bevacizumab group.
There were no major imbalances between the treatment groups
with respect to the use of second-line therapy: XELOX-containing
arms (65%) and FOLFOX4-containing arms (70%). The agents
most commonly used were: irinotecan (56% with FOLFOX4 vs 53%
with XELOX); 5-FU (41 vs 34%); capecitabine (19 vs 14%);
cetuximab (20 vs 18%); and bevacizumab (10 vs 10%).
Overall survival
The OS data as at 31 July 2008 in the ITT population are shown in
Table 2. The corresponding Kaplan–Meier curves for OS are
shown in Figure 2.
For the whole NO16966 study population, median OS was 19.8
months in the pooled XELOX/XELOX-placebo/XELOX-bevacizu-
mab arms vs 19.5 months in the pooled FOLFOX4/FOLFOX4-
placebo/FOLFOX4-bevacizumab arms, with a corresponding HR of
0.95 (97.5% CI 0.85–1.06).
In the pooled XELOX/XELOX-placebo arms, median OS was
19.0 vs 18.9 months in the pooled FOLFOX4/FOLFOX4-placebo
arms, with a corresponding HR of 0.95 (97.5% CI 0.83–1.09).
In the XELOX-bevacizumab arm, median OS was 21.6 vs 21.0
months in the FOLFOX4-bevacizumab arm, with a corresponding
HR of 0.95 (97.5% CI 0.78–1.15).
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FOLFOX4 arm, with a corresponding HR of 0.87 (97.5% CI 0.72–1.05).
FOLFOX4 or a similar regimen was given to 8% of patients in the
pooled XELOX arms as second-line therapy (XELOX, n¼15,
XELOX-placebo, n¼38, XELOX-bevacizumab, n¼29). After
censoring these patients, the median OS was 18.9 months in the
pooled XELOX/XELOX-placebo arms and 18.9 months in the
pooled FOLFOX4/FOLFOX4-placebo arms, with a corresponding
HR of 0.94 (97.5% CI 0.82–1.08), and 21.6 months in the XELOX-
bevacizumab arm and 21.0 months in the FOLFOX4-bevacizumab
arm (HR¼0.93; 97.5% CI 0.76–1.13).
Safety
For the updated safety assessment of XELOX vs FOLFOX4, patients
in the pooled XELOX/XELOX-placebo (n¼655) and pooled
FOLFOX-4/FOLFOX4-placebo (n¼648) arms were compared.
The updated safety analysis showed that little had changed since
the previous analysis (Cassidy et al, 2008a). Predefined adverse
events of special interest and key events pooled by body system are
presented in Table 3.
In general, XELOX and FOLFOX4 had a similar profile of
adverse events. The most common adverse events were gastro-
intestinal (i.e., diarrhoea, nausea, vomiting and stomatitis) and
neurosensory toxicities (i.e., paraesthesia and peripheral neuro-
pathy). However, there were differences between the two regimens
in the rates at which key events occurred. FOLFOX4/FOLFOX4-
placebo was associated with more grade 3/4 neutropenia/
granulocytopenia (44%) and febrile neutropenia (5%) than
XELOX/XELOX-placebo (7 and o1%, respectively). Conversely,
XELOX/XELOX-placebo was associated with more hand-foot
syndrome (all-grade, 31 vs 11%; grade 3, 6 vs 1%) and diarrhoea
(all-grade, 66 vs 61%; grade 3/4, 20 vs 11%) than FOLFOX4/
FOLFOX4-placebo, although the rate of grade 4 diarrhoea was 1%
with both regimens. Rates of grade 3/4 neurosensory toxicity were
similar with both regimens (17%). Cardiac disorders were reported
in 6 (1%) XELOX/XELOX-placebo recipients and 9 (1%) FOLFOX-
4/FOLFOX4-placebo recipients. The addition of bevacizumab did
not alter the similarities and differences in safety profiles between
XELOX and FOLFOX4 (Table 4).
Treatment-related mortality up to 28 days after the last
treatment dose was documented in 11 (1.7%) FOLFOX4/FOL-
FOX4-placebo patients and in 15 (2.3%) XELOX/XELOX-placebo
patients. The respective 60-day all-cause mortality rates were 2.3%
(n¼15) and 3.4% (n¼22).
DISCUSSION
The primary efficacy analysis of study NO16966 showed that
XELOX is non-inferior to FOLFOX4 in terms of progression-free
survival, OS and overall response rate in the first-line treatment of
patients with metastatic colorectal cancer (Cassidy et al, 2008a).
This updated analysis of OS again demonstrates that XELOX and
FOLFOX4 have similar efficacy and supports the primary efficacy
findings. It is also notable that both XELOX and FOLFOX4 were
similar in terms of OS after the addition of bevacizumab.
Overall survival is the most clinically meaningful and objective
measure of efficacy in patients with cancer. However, potential
differences between study treatments can be masked by second-
line and later lines of chemotherapy when this end point is used
(Di Leo et al, 2004). In study NO16966, there were no restrictions
regarding crossover or salvage therapies after the completion of
study treatment. It is therefore possible that crossover to the
alternate study treatment was a confounding factor in the present
analysis. To allow for this, we performed a separate analysis in
which all patients randomised to XELOX and who received
FOLFOX as second-line therapy were censored. The results were
consistent with those obtained in the ITT population and again
support the similar efficacy of XELOX vs FOLFOX4.
The question of whether or not capecitabine is non-inferior to
5-FU/FA when given in combination with oxaliplatin in metastatic
colorectal cancer has now been addressed in six different
randomised phase III trials (Dı ´az-Rubio et al, 2007; Porschen
et al, 2007; Rothenberg et al, 2008; Cassidy et al, 2008a; Comella
et al, 2009; Ducreux et al, 2011), of which NO16966 is the largest.
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Figure 1 The CONSORT flowchart.
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sThe other five studies, which involved 300–600 patients each, were
largely supportive of NO16966. In three of the studies, the efficacy
of XELOX or OXXEL was shown to be similar to that of 5-FU/FA-
oxaliplatin regimens (Rothenberg et al, 2008; Comella et al, 2009;
Ducreux et al, 2011), whereas the remaining two were inconclusive
with regard to non-inferiority (Dı ´az-Rubio et al, 2007; Porschen
et al, 2007). Since the completion of the phase III trials, three
separate meta-analyses of relevant studies comparing capecitabine
or 5-FU/FA plus oxaliplatin in patients with metastatic colorectal
cancer have been performed (Arkenau et al, 2008; Cassidy et al,
2008b; Cuppone et al, 2008). Even though each meta-analysis
included a different selection of phase II and III studies, the
outcomes were very similar with respect to both progression-free
survival (HR/relative risk 0.98–1.04) and OS (1.02–1.04). Thus,
there is now strong evidence to support the non-inferiority of
capecitabine when used in combination with oxaliplatin vs
infusional 5-FU-based oxaliplatin regimens in the treatment of
patients with metastatic colorectal cancer, both in the first- and
second-line settings.
It is therefore likely that other considerations, such as
tolerability profile, convenience, patient preference and cost, will
assume greater importance when selecting the fluoropyrimidine
backbone of a chemotherapy regimen. With regard to tolerability,
both XELOX and FOLFOX have a similar profile of adverse events,
but XELOX is associated with more grade 3 diarrhoea and hand-
foot syndrome, whereas FOLFOX is associated with more grade
Table 1 Baseline patient characteristics (ITT population)
FOLFOX4
(n¼317)
FOLFOX4-
placebo
(n¼351)
FOLFOX4-
bevacizumab
(n¼349)
XELOX
(n¼317)
XELOX-
placebo
(n¼350)
XELOX-
bevacizumab
(n¼350)
Characteristic No. % No. % No. % No. % No. % No. %
Gender
Male 204 64 186 53 205 59 194 61 205 59 213 61
Female 113 36 165 47 144 41 123 39 145 41 137 39
Age, years
Median 62 60 60 61 61 61
Range 24–83 26–83 19–82 24–84 18–83 18–86
ECOG performance status
0 163 51 211 60 198 57 160 50 207 59 207 59
1 154 49 138 40 147 43 157 50 143 41 142 41
2 0 00 0 0 00 0 0 01 o1
Primary tumour site
Colorectal 17 5 25 7 28 8 30 9 30 9 32 9
Colon 200 63 232 66 223 64 204 64 233 67 236 67
Rectal 100 32 94 27 98 28 83 26 87 25 82 23
Stage at first diagnosis
Local regional 144 45 141 40 128 37 133 42 138 39 122 35
Metastatic 173 55 210 60 221 63 184 58 212 61 228 65
Number of metastatic sites
0 1 0.3 1 0.3 1 0.3 0 0 0 0 0 0
1 118 37.2 142 40.5 150 43.0 127 40.1 155 44.3 134 38.3
2 121 38.2 122 34.8 132 37.8 106 33.4 112 32.0 121 34.6
3 47 14.8 65 18.5 44 12.6 55 17.4 58 16.6 64 18.3
X4 30 9.5 21 6.0 22 6.3 29 9.1 25 7.1 31 8.9
Alkaline phosphatase
Abnormal 135 43 147 42 146 42 132 42 149 43 156 45
Normal 182 57 201 58 199 58 183 58 200 57 191 55
Previous adjuvant therapy
No 234 74 266 76 261 75 229 72 259 74 274 78
Yes 83 26 85 24 88 25 88 28 91 26 76 22
Abbreviations: ITT¼intent-to-treat; ECOG¼Eastern Cooperative Oncology Group; FOLFOX4¼infused fluorouracil, folinic acid and oxaliplatin; XELOX¼capecitabine and
oxaliplatin.
Table 2 Overall survival by treatment subgroup (ITT population)
Treatment subgroup
comparison
No. of
events
Median
time
to event
(months)
Hazard ratio
(97.5% CI)
FOLFOX4/FOLFOX4-placebo/
FOLFOX4-bevacizumab
847 19.5 0.95 (0.85–1.06)
XELOX/XELOX-placebo/
XELOX-bevacizumab
820 19.8
FOLFOX4/FOLFOX4-placebo 573 18.9 0.95 (0.83–1.09)
XELOX/XELOX-placebo 546 19.0
FOLFOX4-bevacizumab 274 21.0 0.95 (0.78–1.15)
XELOX-bevacizumab 274 21.6
FOLFOX4 284 17.7 0.87 (0.72–1.05)
XELOX 266 18.8
Abbreviations: ITT¼intent-to-treat; CI¼confidence interval; FOLFOX4¼infused
fluorouracil, folinic acid and oxaliplatin; XELOX¼capecitabine and oxaliplatin.
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s3/4 neutropenia and febrile neutropenia (Rothenberg et al, 2008;
Ducreux et al, 2011). This is supported by the updated safety data
from NO16966 in the present paper.
In terms of convenience, XELOX requires fewer planned office
visits than the FOLFOX regimens because oxaliplatin is adminis-
tered every 3 weeks (rather than every 2 weeks) and because
1.0
FOLFOX-4 / FOLFOX-4 + placebo / FOLFOX-4
+ bevacizumab n=1017; 847 events
XELOX / XELOX + placebo / XELOX
+ bevacizumab n=1017; 820 events
HR = 0.95 (97.5% CI: 0.85–1.06) (ITT)
HR = 0.96 (97.5% CI: 0.86–1.08) (EPP)
FOLFOX-4 + bevacizumab
n=349; 274 events
XELOX + bevacizumab
n=350;  274 events
HR = 0.95 (97.5% CI: 0.78–1.15) (ITT)
HR = 0.95 (97.5% CI: 0.78–1.16) (EPP)
FOLFOX-4 / FOLFOX-4 + placebo
n=668; 573 events
XELOX / XELOX + placebo
n=667;  546 events
HR = 0.95 (97.5% CI: 0.83–1.09) (ITT)
HR = 0.97 (97.5% CI: 0.84–1.11) (EPP)
XELOX
n=317; 266 events
HR = 0.87 (97.5% CI: 0.72–1.05) (ITT)
HR = 0.89 (97.5% CI: 0.73–1.08) (EPP)
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Figure 2 Overall survival for FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab vs XELOX/XELOX-placebo/XELOX-bevacizumab (A), FOLFOX4/
FOLFOX4-placebo vs XELOX/XELOX-placebo (B), FOLFOX4-bevacizumab vs XELOX-bevacizumab (C) and FOLFOX4 vs XELOX (D) (ITT population).
Table 3 Adverse events of special interest to chemotherapy and key
events pooled by body system (treatment-related and unrelated)
FOLFOX4/
FOLFOX4-placebo
(n¼648)
XELOX/
XELOX-placebo
(n¼655)
All-grade Grade 3/4 All-grade Grade 3/4
No. % No. % No. % No. %
All events 644 99 506 78 649 99 468 72
Body system
Gastrointestinal
disorders
603 93 167 26 606 93 216 33
Blood/lymphatic
disorders
448 69 318 49 312 48 104 16
Infections/infestations 292 45 66 10 210 32 45 7
Events of special interest
Neurosensory
toxicity
a
515 80 107 17 534 82 114 17
Diarrhoea 394 61 74 11 429 66 133 20
Nausea/vomiting 452 70 47 7 464 71 52 8
Stomatitis 242 37 13 2 140 21 8 1
Neutropenia/
granulocytopenia
379 59 282 44 180 28 46 7
Febrile neutropenia — — 31 5 — — 6 o1
Hand-foot syndrome 70 11 8
b 1
b 201 31 40
b 6
b
Abbreviations: FOLFOX4¼infused 5-fluorouracil, folinic acid and oxaliplatin;
XELOX¼capecitabine and oxaliplatin.
aPooled term that includes burning sensation,
dysaesthesia, hyper or hypoaesthesia, neuropathic pain, neuropathy, peripheral
neuropathy, neurotoxicity, paraesthesia, peripheral (sensi)motor neuropathy,
(chronic) polyneuropathy, sensory disturbance or loss, skin burning sensation,
temperature intolerance, neuralgia, peroneal nerve palsy, autonomic neuropathy.
bGrade 3 events only.
Table 4 Adverse events of special interest to chemotherapy and key
events pooled by body system (treatment-related and unrelated)
FOLFOX4-
bevacizumab
(n¼342)
XELOX-
bevacizumab
(n¼353)
All-grade Grade 3/4 All-grade Grade 3/4
No. % No. % No. % No. %
All events 340 99 289 85 351 99 266 75
Body system
Gastrointestinal
disorders
320 94 94 28 325 92 132 37
Blood/lymphatic
disorders
229 67 159 47 125 35 44 13
Infections/infestations 164 42 31 9 137 39 21 6
Events of special interest
Neurosensory
toxicity
a
281 82 61 18 296 84 64 18
Diarrhoea 219 64 44 13 224 64 77 22
Nausea/vomiting 235 69 25 7 252 71 38 11
Stomatitis 141 41 12 4 102 29 7 2
Neutropenia/
granulocytopenia
189 55 138 40 70 20 25 7
Febrile neutropenia — — 15 4 — — 4 1
Hand-foot syndrome 47 14 6
b 2
b 141 40 42
b 12
b
Abbreviations: FOLFOX4¼infused 5-fluorouracil, folinic acid and oxaliplatin;
XELOX¼capecitabine and oxaliplatin.
aPooled term that includes burning sensation,
dysaesthesia, hyper or hypoaesthesia, neuropathic pain, neuropathy, peripheral
neuropathy, neurotoxicity, paraesthesia, peripheral (sensi)motor neuropathy,
(chronic) polyneuropathy, sensory disturbance or loss, skin burning sensation,
temperature intolerance, neuralgia, peroneal nerve palsy, autonomic neuropathy.
bGrade 3 events only.
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scapecitabine is taken orally. This is supported by resource use data
from NO16966, which showed that the need for drug administra-
tion visits, central venous access and patient travel and time were
reduced with XELOX vs FOLFOX4 (Scheithauer et al, 2007). When
costs were assigned to these data, the total direct costs of both
regimens were similar, whereas the indirect costs of XELOX were
considerably less than those of FOLFOX4 (Garrison et al, 2007).
Similar observations were made in a cost comparison of
capecitabine ± oxaliplatin vs 5-FU ± oxaliplatin based on a
retrospective analysis of a US medical claims database (Chu et al,
2009). Modified FOLFOX regimens, which involve a single 46- to
48-h infusion of 5-FU, are likely to be less costly than unmodified
FOLFOX regimens (Garrison et al, 2007), although a complete
assessment vs XELOX has yet to be performed.
In conclusion, updated survival data from study NO16966 show
that XELOX is similar to FOLFOX4, confirming the primary
analysis of progression-free survival. XELOX can be considered as
a routine first-line treatment option for patients with metastatic
colorectal cancer.
ACKNOWLEDGEMENTS
Financial support for this research was provided by Roche.
In addition to the investigators in the author list, we acknow-
ledge the following investigators who also participated in this trial:
Australia: S Begbie, I Burns, P Gibbs, D Goldstein, P Mainwaring,
J McKendrick, M Michael, N Pavlakis, T Price, M Schwartz,
J Shapiro, B Stein, G Van Hazel; Austria: J Thaler; Brazil: C Andrade,
GI s m a e l ,AM a l z y n e r ;Canada: J-P Ayoub, S Berry, R Burkes,
P Dube, B Findlay, C Fitzgerald, A Gurjal, D Jonker, L Kaizer, P
Klimo, B Lesperance, P Major, B Melosky, L Siu, M Taylor, K Virik,
R Wierzbicki, J Wilson, A Wong; China: FF e n g - Y i ,YH e ,SJ i a o ,JL i ,
R Luo, L Pan, S Song, H Wang, J Xiong, B Yu, S-Y Yu; Czech
Republic: D Feltl, I Kocakova, M Kuta; Denmark: BV Jenson,
P Pfeiffer; Finland: P Bono, P Kellokumpu-Lehtinen, S Pyrhoenen;
France: F-X Caroli-Bosc, B Coudert, C Debrigode, J-P Delord, G Des
Guetz, J-Y Douillard, E Francois, G Freyer, C Garnier, M Gil Delgado,
F Goldwasser, F Husseini, P Michel, S Negrier, X Pivot, P Rougier;
Germany: M Clemens, A Hochhaus, T Hoehler, S Kanzler, S Kubicka,
F Kullmann, L Mantovani, W-H Schmiegel, H-J Schmoll, R
Voigtmann; Guatemala: CE Hernandez-Monroy, LM Zetina Toache;
Hong Kong: AC h a n ;Hungary: MD a n k ,IL a n g ,TP i n t e r ,MS z u c s ;
Ireland: D Fennelly, M Keane, J Kennedy, S O’Reilly; Israel: AB e n y ,
A Hubert, A Sella, S Stemmer; Italy: C Boni, S Brugnatelli, S Cascinu,
PF Conte, A Contu, S Monfardini, R Rosso, S Salvagni, A Sobrero;
Republic of Korea: YS Park; Mexico: G Calderillo, E Leo ´n; New
Zealand: BR o b i n s o n ;Norway: L Balteskard, T Guren, H Soerbye;
Panama: E Diaz-Correa; Portugal: S Barroso, P Cortes; Russian
Federation: VP Kharchenko, M Lichinitser, GM Manikhas,
V Moiseenko; South Africa: G Cohen, C Kukard, J Raats, C Slabber,
D Vorobiof; Spain: JE Ales-Martinez, A Anton Torres, J Aparicio,
E Aranda, A Cervantes, P Escudero, J Feliu, C Fernandez-Martos,
R Garcia-Carbonero, P Garcia-Alfonso, E Gonzalez Flores,
C Gravalos, J Maurel, M Navarro-Garcia, F Rivera, R Salazar, I
Sevilla, J Tabernero; Sweden: B Glimelius, H Letocha, U Loenn,
DP e d e r s e n ;Switzerland: M Borner, A Roth; Taiwan: T-Y Chao, P-M
C h e n ,A LC h e n g ,T - SY a n g ;Thailand: S Chakrapee-Sirisuk,
AN Kiatikajornthada, A Sookprasert; Turkey: G Demir, E Goker;
United Kingdom: E Bessell, P Chakraborti, F Coxon, D Cunningham,
S Falk, F Daniel, R Glynne-Jones, M Hill, T Iveson, A Maraveyas,
T Maughan, D Rea, L Samuel, C Topham; United States:
N Abramson, B Amin, B Bhaskar, L Campos, R Castillo, V Chang,
P DeSimone, P Eisenberg, JA Ellerton, T Ervin, G Frenette, J Fuloria,
H Gomolin, MGreenblatt, G Gross, WJM Hrushesky, D Irwin,
M Kane, D Kapur, B Kasimis, KS Kumar, F-C Lee, MW Lee,
L Martin, R Mena, J Neidhart, J Pennacchi, E Poplin, C Redfern, R
Reiling, M Saleh, L Schwartzberg, W Sikov, A Solky, P Stella, S
Thomas, R Vivacqua, R Yanagihara. Support for third-party
writing assistance for this manuscript, furnished by Miller
Medical Communications, was provided by F. Hoffmann–La
Roche Ltd.
REFERENCES
Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H,
Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R
(2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/
leucovorin in patients with metastatic colorectal cancer: a pooled
analysis of randomized trials. J Clin Oncol 26: 5910–5917
Cassidy J, Clarke S, Diaz Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirze ´n F, Saltz L (2008a)
A randomized phase III study of capecitabine plus oxaliplatin (XELOX)
versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line
therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006–2012
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R,
Koski S, Sirzen F, Gilberg F, Saltz L (2008b) XELOX vs FOLFOX4: update
of efficacy results from XELOX-1/NO16966, a randomized phase III trial
of first-line treatment for patients (pts) with metastatic colorectal cancer
(MCRC). Presented at the ASCO GI Cancers Symposium: Orlando,
Florida, USA, 25–27 January (abstract 341)
Chu E, Schulman KL, Zelt S (2009) Costs associated with complications are
lower with capecitabine than with 5-fluorouracil in patients with
colorectal cancer. Cancer 115: 1412–1423
Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G,
Maiorino L, Palmeri S, Condemi G, Southern Italy Cooperative
Oncology Group (2009) Randomised trial comparing biweekly oxalipla-
tin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/
leucovorin in metastatic colorectal cancer patients: results of the
Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin
Oncol 135: 217–226
Cuppone F, Bria E, Sperduti I, Di Maio M, Carlini P, Milella M, Cognetti F,
Terzoli E, Giannarelli D (2008) Capecitabine (CAP) versus 5-fluorouracil
(FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy
(CT) for advanced colorectal cancer (ACRC): meta-analysis of rando-
mized clinical trials (RCT). J Clin Oncol 26: 192s (Suppl; abstract 4056)
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J,
Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D,
Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F,
Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:
2938–2947
Dı ´az-Rubio E, Tabernero J, Go ´mez-Espan ˜a A, Massutı ´ B, Sastre J,
Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonza ´lez-
Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative
Group for the Treatment of Digestive Tumors Trial (2007) Phase III
study of capecitabine plus oxaliplatin versus continuous infusion
fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal
cancer: final report of the Spanish Cooperative Group for the Treatment
of Digestive Tumors trial. J Clin Oncol 25: 4224–4230
Di Leo A, Buyse M, Bleiberg H (2004) Is overall survival a realistic primary
end point in advanced colorectal cancer studies? A critical assessment
based on four clinical trials comparing fluorouracil plus leucovorin with
the same treatment combined either with oxaliplatin or with CPT-11.
Ann Oncol 15: 545–549
Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis
A, Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard JY, GI
Group of the French Anti-Cancer Centers (2011) Capecitabine plus
oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin
(FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Int J Cancer 128: 682–690
Garrison L, Cassidy J, Saleh M, Lee F, Mena R, Fuloria J, Chang V, Ervin T,
Stella P, Saltz L (2007) Cost comparison of XELOX compared to
XELOX vs FOLFOX4 in first-line colorectal cancer
J Cassidy et al
63
British Journal of Cancer (2011) 105(1), 58–64 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sFOLFOX4 with or without bevacizumab (bev) in metastatic colorectal
cancer. J Clin Oncol 25: 18S (Suppl, abstract 4074)
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J,
Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO,
Wong R (2001) Comparison of oral capecitabine versus intravenous
fluorouracil plus leucovorin as first-line treatment in 605 patients with
metastatic colorectal cancer: results of a randomized phase III study. J
Clin Oncol 19: 2282–2292
Porschen R, Arkenau H-T, Kubicka S, Greil R, Seufferlein T, Freier W,
Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll
HJ, AIO Colorectal Study Group (2007) Phase III study of capecitabine
plus oxaliplatin compared with fluorouracil and leucovorin plus
oxaliplatin in metastatic colorectal cancer: a final report of the AIO
Colorectal Study Group. J Clin Oncol 25: 4217–4223
Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S,
Siu LL, Laguerre S, Cunningham D (2008) Capecitabine plus oxaliplatin
(XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4)
as second-line therapy in metastatic colorectal cancer: a randomized
phase III noninferiority study. Ann Oncol 19: 1720–1726
Saltz L, Clarke S, Dı ´az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirze ´n F, Cassidy J (2008)
Efficacy and safety of bevacizumab in combination with oxaliplatin-
based chemotherapy as first-line therapy in metastatic colorectal cancer:
a randomized phase III study. J Clin Oncol 26: 2013–2019
Scheithauer W, Cassidy J, Figer A, Wong R, Koski S, Lichinitser M, Yang T,
Clarke S, Diaz-Rubio E, Garrison L (2007) A comparison of medical
resource use for 4 chemotherapy regimens as first-line treatment
for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ±
bevacizumab (A). J Clin Oncol 25: 18S (Suppl, abstract 4098)
Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J,
Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D,
Koralewski P, Kro ¨ning H, Maroun J, Marschner N, McKendrick J,
Pawlicki M, Rosso R, Schu ¨ller J, Seitz JF, Stabuc B, Tujakowski J, Van
Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant
treatment for stage III colon cancer. N Engl J Med 352: 2696–2704
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R,
Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga
G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM,
Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral
capecitabine compared with intravenous fluorouracil plus leucovorin in
patients with metastatic colorectal cancer: results of a large phase III
study. J Clin Oncol 19: 4097–4106
XELOX vs FOLFOX4 in first-line colorectal cancer
J Cassidy et al
64
British Journal of Cancer (2011) 105(1), 58–64 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s